Abnormal Expression, Highly Efficient Detection and Novel Truncations of Midkine in Human Tumors, Cancers and Cell Lines
Overview
Authors
Affiliations
We detected aberrant Midkine (MK) expressions in human insulinoma and pancreatic cancer tissues by immunohistochemistry, revealing its potential role in tumorigenesis/carcinogenesis. With a nested-touchdown PCR program we were able to detect the tMK in all human tumor/cancer tissues and cancer/tumor cell lines. Detection of MK in the peripheral cells and precancerous lesions implies its potential for early cancer/tumor diagnosis. Furthermore, we have discovered two novel truncations of the MK, tMKB and tMKC, respectively, in the disease specimens. Our data not only provide an efficient methodology potentially for clinical application but also shed light on the molecular mechanism underlying the role for MK in tumorigenesis/carcinogenesis.
Midkine-A novel player in cardiovascular diseases.
Majaj M, Weckbach L Front Cardiovasc Med. 2022; 9:1003104.
PMID: 36204583 PMC: 9530663. DOI: 10.3389/fcvm.2022.1003104.
Babak M, Meier S, Huber K, Reynisson J, Legin A, Jakupec M Chem Sci. 2018; 6(4):2449-2456.
PMID: 29308157 PMC: 5647740. DOI: 10.1039/c4sc03905j.
Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.
Jones D Br J Pharmacol. 2014; 171(12):2925-39.
PMID: 24460734 PMC: 4055197. DOI: 10.1111/bph.12601.
Midkine: a novel prognostic biomarker for cancer.
Jono H, Ando Y Cancers (Basel). 2013; 2(2):624-41.
PMID: 24281085 PMC: 3835095. DOI: 10.3390/cancers2020624.
Rice G, Edgell T, Autelitano D J Exp Clin Cancer Res. 2010; 29:62.
PMID: 20525245 PMC: 3161349. DOI: 10.1186/1756-9966-29-62.